Apexigen, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Xiaodong Yang
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 75 Shoreway Road San Carlos CA United States of America 94070
- IPO Date
- Feb 22, 2021
- CIK
- 0001814140
- Website
- apexigen.com
- Similar Companies
- Business
- Apexigen, Inc. (APGN) is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of cancer. The company engineers proprietary antibodies using its APXi platform, which generates antibodies with enhanced effector functions to stimulate a patient's immune system against tumors; its lead product candidate, APX3330, is an oral small molecule inhibitor targeting APE1/Ref-1 for oncology indications including pancreatic cancer and cutaneous T-cell lymphoma; additional pipeline assets include APG777, a bispecific antibody targeting OX40 and CD39, and preclinical programs in immuno-oncology. Apexigen offers discovery and development services for custom antibody solutions, including bispecific antibodies and antibody-drug conjugates, targeting pharmaceutical and biotech partners in the immuno-oncology space. Founded in 2007 and headquartered in San Carlos, California, the company operates primarily in the United States with a focus on global clinical trials and partnerships in North America, Europe, and Asia. In recent developments, Apexigen completed a business combination with iCarTab Bio in December 2024, becoming a publicly traded entity on Nasdaq under the ticker APGN, and announced positive interim data from its Phase 1b/2 trial of APX3330 in September 2025, alongside strategic expansions into combination therapies with PD-1 inhibitors.
APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
Shareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis Oncology
Why Is Apexigen (APGN) Stock Up 31% Today?
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?
Apexigen Announces Review of Strategic Alternatives and Restructuring
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
Apexigen Announces Approximately $2.8 Million Private Placement Financing
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
Form 8.3 - Applegreen plc
Form 8.3 - Applegreen plc
Form 8.3 - APPLEGREEN PLC
Form 8.3 - Applegreen plc